Compare LI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | VTRS |
|---|---|---|
| Founded | 2015 | 1961 |
| Country | China | United States |
| Employees | 30728 | 30000 |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 17.2B |
| IPO Year | N/A | 2019 |
| Metric | LI | VTRS |
|---|---|---|
| Price | $17.66 | $14.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $19.66 | $13.50 |
| AVG Volume (30 Days) | 2.6M | ★ 8.0M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $18.98 | $4.41 |
| Revenue Next Year | $22.72 | $1.96 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.71 | $8.19 |
| 52 Week High | $32.03 | $16.47 |
| Indicator | LI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 60.66 |
| Support Level | $17.45 | $12.90 |
| Resistance Level | $18.94 | $15.22 |
| Average True Range (ATR) | 0.33 | 0.40 |
| MACD | -0.11 | 0.11 |
| Stochastic Oscillator | 20.29 | 74.86 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.